To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Patients With Hepatic Impairment and Healthy Subjects
Completed · Phase 1
Conditions studied: Solid Tumors
In brief
A study to assess the pharmacokinetics, safety and tolerability of Selumetinib (AZD6244, ARRY-142886) in patients with hepatic impairment and healthy subjects.
Key facts
- Study ID
- NCT02063230
- Run by
- AstraZeneca
- People needed
- 32
- Starts
- 2014-03-01
- Expected to finish
- 2014-11-01
- Last updated by the study team
- 2016-07-21
Who can join
Age: 18 and older, up to 130. Sex: any. Healthy volunteers: accepted.
Where it is running
- Research Site — Orlando, Florida, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.